MORRISTOWN, N.J., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, announced today that the Company will report financial results for the third quarter ended September 30, 2016, after the market close on Thursday, November 10, 2016. John Sedor, Chairman and Chief Executive Officer, and Graham Miao, President and Chief Financial Officer, will host a conference call to discuss the results.
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its integrated Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Matthew P. Duffy, 212-915-0685
LifeSci Advisors, LLC
Pernix Therapeutics Holdings, Inc.